DBS Technologies Pty Ltd is developing an innovative device providing adaptive deep brain stimulation for people with Parkinson’s disease.
This project will develop an innovative deep brain stimulation (DBS) device to radically improve therapy for people living with Parkinson’s disease (PD). This device will utilise a signal originating in the brain to automatically control therapy, leading to better quality of life and reduce side effects for PD patients.
PD is characterised by progressive and debilitating loss of control of movement, with symptoms including tremor, slowness, and muscle rigidity. Although medications are usually helpful, many patients require DBS, an established therapy based on electrical brain stimulation delivered via implanted electrodes. Today's DBS devices are limited to providing constant stimulation, while the symptoms of PD vary greatly over time. DBS Technologies adaptive device will continually and autonomously adjust stimulation to optimise benefit for each patient.
BTB Round: One
Project Partners: The Bionics Institute of Australia
- MTPConnect Grant: $1,064,063
- Industry Contribution: $1,963,405
Duration: April 2020 – March 2022